

**INFORMATION DISCLOSURE TO THE SHAREHOLDERS OF
PT SARANA MEDITAMA METROPOLITAN TBK (“COMPANY”)
IN ACCORDANCE WITH THE PROPOSED CAPITAL INCREASE WITHOUT PRE-EMPTIVE RIGHTS
 (“PMTHMETD”) FOR THE IMPLEMENTATION OF MANAGEMENT AND EMPLOYEES SHARES
 OWNERSHIP PROGRAM (“MESOP PROGRAM”)**

This Information Disclosure is submitted in order to comply with Financial Services Authority Regulation Number 14/POJK.04/2019 concerning Amendment to Financial Services Authority Regulation Number 32/POJK.04/2015 concerning Capital Increases in Public Companies With Pre-Emptive Rights (“**POJK No. 14/2019**”).



We Care with Passion

PT SARANA MEDITAMA METROPOLITAN Tbk
Domiciled in East Jakarta

Business activities:

Human Health Activities by carrying out Main Business Activities (Private Hospital Activities, Practice Activities of General Practitioner, Specialist Doctors, and Dentists, as well as Medical Evacuation Activities) and other activities to support the Main Business Activities.

Headquarters:

Jl. Pulomas Barat VI No. 20, Kayu Putih, Pulo Gadung,
East Jakarta 13210, Indonesia.
Phone. 150 789
Website: www.emc.id
Email: corsec@emc.id

This information is announced on the websites of IDX and the Company in connection with the Company's plan to conduct PMTHMETD in the framework of the MESOP Program, in which its implementation requires the approval of the shareholders that to be requested through the Extraordinary General Meeting of Shareholders which will be held on Tuesday, 9 June 2026 (“**EGMS**”) as announced through the websites of the Company, IDX, and KSEI on 26 April 2026 (“**GMS Announcement**”).

The Board of Directors and Board of Commissioners of the Company hereby declare that they are fully responsible for the accuracy of the information contained in this Disclosure of Information that was drafted after exercising a reasonable examination, and also confirm that the material information related to the MESOP Program contained in this Disclosure of Information is true and there are no other material facts that are not disclosed or omitted which may result in the information in this Disclosure of Information being untrue and/or misleading.

This Information Disclosure is issued on 26 April 2026

DEFINITION

“The Company’s AoA”	:	The Company’s Articles of Association were last amended based on Deed No. 69 dated March 27, 2026, drawn up before Aulia Taufani, S.H., a Notary in South Jakarta, which has been notified to and received by the Minister of Law of the Republic of Indonesia as evidenced by the Acknowledgment of Receipt of Notification of Amendment to the Articles of Association No. AHU-AH.01.03-0093588 dated March 31, 2026.
“BAE”	:	Security Administration Bureau, in which party that carries out the administration of the Company’s shares appointed by the Company, PT Bima Registra, with domicile in Jakarta.
“IDX”	:	Stands for Indonesia Stock Exchange, a Limited Liability Company incorporated under the laws of the Republic of Indonesia as well as domicile in Jakarta, and which this Company’s shares are listed at.
“Shareholder Register”	:	A list containing the names of the shareholders in the Company as stipulated under the Company Law.
“Company Group”	:	The Company and the Controlled Companies.
“Trading Days”	:	The day when IDX or the substituting legal body organize stock exchange activities pursuant to the applicable laws and regulations and other provisions applied by stock exchange in question and when the banks process the clearance.
“Calendar Days”	:	Any day in 1 (one) year according to Gregorian calendar system without any exception, including Sundays and national holidays as decided at any time by the Government of Republic of Indonesia and normal working days, which due to certain conditions have been set by the Government of Indonesia as not normal working days.
“Working Days”	:	The days of Monday through Friday, except national holidays or other holidays as decided by the Government of Republic of Indonesia.
“KSEI”	:	Stands for PT Kustodian Sentral Efek Indonesia, having domicile in Jakarta in the capacity of Securities Depository and Settlement Institute as stipulated under UUPM.
“MOL”	:	Stands for The Minister of Law of the Republic of Indonesia.
“Financial Services Authority” or “OJK”	:	An independent institute as referred to in Law No. 21 of 2011 concerning Financial Services Authority (“ OJK Law ”) with duties and responsibilities inclusive of regulating and overseeing financial service activities in banking sector, capital market, insurance, pension fund, financing institutes and other finance institutes, which as from 31 December 2012, OJK has been assigned as institute to replace and as such receive the rights and obligations necessary to perform the regulatory and supervisory functions of Bapepam and/or Bapepam and LK pursuant to provisions of Article 55 of OJK Law.

- “Controlled Companies”** : Any company that are controlled either directly or indirectly by the Company from time to time, include:
1. PT Sarana Meditama International;
 2. PT Sarana Meditama Anugerah;
 3. PT Kurnia Sejahtera Utama;
 4. PT Utama Pratama Medika;
 5. PT Unggul Pratama Medika;
 6. PT Kedoya Adyaraya Tbk; dan
 7. PT Sinar Medika Sejahtera.
- “Shareholders”** : The parties that shall reserve the right to reap benefits from Company’s shares kept and administered in security accounts of KSEI, registered in Company’s Shareholder Register administered by Security Administration Bureau namely PT Bima Registra.
- “Independent Shareholders”** : Shareholders who do not have a personal economic interest in relation to the PMTHMETD, and:
- a. they are not a member of the Board of Directors, member of the Board of Commissioners, major shareholder, and controlling the shareholder of the Company; or
 - b. they are not an affiliate of the members of the Board of Directors, members of the Board of Commissioners, major shareholders, and the controlling shareholder of the Company.
- “Rule No. I-A”** : Decision of the IDX Board of Directors Number: : Kep-00045/BEI/03-2026 dated 31 March 2026 concerning Amendment to Regulation Number I-A concerning the Listing of Shares and Equity Securities Other than Shares Issued by the Listed Company which replaces the Decree of the IDX Board of Directors Number: Kep-00101/BEI/12-2021 dated 21 December 2021 and its attachments.
- “MESOP Program Participants”** : All employees, members of the Board of Directors, and members of the Board of Commissioners who meet the following requirements:
1. members of the Board of Commissioners of the Company (except for the Independent Commissioners) and Controlled Companies approved by the Nomination and Remuneration Committee of the Company who served at the date of free shares distribution as part of the compensation;
 2. members of the Board of Directors of the Company and Controlled Companies who are proposed by the Board of Directors and approved by the Nomination and Remuneration Committee of the Company who served at the date of free shares distribution as part of the compensation; and
 3. permanent employees of the Company and Controlled Companies appointed by the Board of Directors of the Company with the following requirements: (i) have a position with a minimum rank of Grade N-3 and above; (ii) recorded in the employees data of the Company and the Controlled Companies; and (iii) have worked for at least 6 (six) months prior to the date of free shares distribution as part of compensation.

- “POJK No. 14/2019”** : OJK Regulation No. 14/POJK.04/2019 dated 30 April 2019 concerning Amendment to the Financial Services Authority Regulation No. 32/POJK.04/2015 concerning Capital Increases in Public Companies with Pre-Emptive Rights.
- “POJK No. 15/2020”** : OJK Regulation No. 15/POJK.04/2020 dated 21 April 2020 concerning the Plan and Implementation of General Meeting of Shareholders of Public Companies.
- “EGMS”** : Extraordinary General Meeting of Shareholders of the Company, to be held on Tuesday, June 9, 2026.
- “Shares”** : All shares that have been issued and fully paid in the Company on the date of this Disclosure of Information is published.
- “New Shares”** : A maximum of 34,329,265 (thirty four million three hundred twenty nine thousand two hundred sixty five) new shares to be issued from the Company’s portfolio with a nominal value of Rp20,- per share or a maximum of 0.2% (zero point two percent) of the issued and paid-up capital in the Company, amounting to 17,164,632,545 (seventeen billion one hundred sixty four million six hundred thirty two thousand five hundred forty five) shares based on The Company's AoA for the implementation of the MESOP Program by the Company.
- “Capital Market Law”** : Law No. 8 of 1995 dated 10 November 1995 concerning the Capital Market, based on the State Gazette of the Republic of Indonesia No. 64 of 1995, Supplement No. 3608.
- “Company Law”** : Law No. 40 of 2007 dated 16 August 2007 concerning Limited Liability Companies, based on the State Gazette of the Republic of Indonesia No. 106 of 2007, Supplement No. 4746.

THE PURPOSE AND OBJECTIVES OF MESOP PROGRAM

In the recent years, the Company has achieved better performance and growth that strengthen the Company's capital structure. The Company believes that such improvement can occur because of the commitment and hard work of the management and employees. Therefore, as a form of appreciation and effort from the Company to continually optimize performance and maintain sustainable growth for the Company, the Company plans to implement the Management and Employee Stock Ownership Program ("**MESOP Program**"). The MESOP Program also aims to increase sense of belonging for each of the management member and employee of the Company and Controlled Companies ("**Company Group**"), both towards to the Company and the Company Group. Through MESOP Program, the Company hopes that the work performance of MESOP Program Participants can be improved so that in the end, the Company Group's performance can also be improved.

The Company plans to conduct PMTHMETD in order to implement the MESOP Program by issuing a maximum of 34,329,265 (thirty four million three hundred twenty nine thousand two hundred sixty five) shares or equivalent to 0.2% (zero point two percent) of the total issued and paid-up capital in the Company, in which the new shares are to be issued to the MESOP Program Participants with free shares ("**New Shares**").

MESOP Program shall be conducted by the Company in accordance with the Financial Services Authority Regulation Number 14/POJK.04/2019 concerning Amendment of the Financial Services Authority Regulation Number 32/POJK.04/2015 concerning Capital Increases in Public Companies With Pre-emptive Rights ("**POJK No. 14/2019**").

COMPANY OVERVIEW

A. Company Background

The Company was established under the name PT Sarana Meditama Metropolitan and was initially engaged in the business of engineering work, general trading, services, industry and crafts, agency, and investment in buildings. The establishment is stated in the Deed No. 27 dated 13 November 1984, drawn up before Budiarti Karnadi S.H., Notary in Jakarta, which has been approved by the Minister of Justice of the Republic of Indonesia through Decree No. C2-933.HT.01.01.TH.85 dated 25 February 1985 ("**Deed of Establishment**"). The Company then listed its shares on the IDX or conducted go-public on 11 January 2013. By referring to the provisions of the Company Law and other laws and regulations in the capital market sector, the name PT Sarana Meditama Metropolitan was changed to PT Sarana Meditama Metropolitan Tbk as a result of being listed publicly.

The Company is domiciled in East Jakarta with its headquarters located at Jalan Pulomas Barat VI No. 20, RT 009/RW 06, Kayu Putih Village, Pulo Gadung District, East Jakarta Administrative City, Special Capital Region of Jakarta.

The shareholders of the Company have approved changes to the entire articles of association, among others, to be adjusted to POJK No. 15/2020 which is based on Deed No. 33 dated 10 May 2021, drawn up before Aulia Taufani, S.H., Notary in South Jakarta, which has been notified to and accepted by the Menkumham through the Letter of Acceptance of Notification of Amendment to the Articles of Association No. AHU-AH.01.03-0304276 dated 11 May 2021.

In addition, the articles of association of the Company were last amended pursuant to Deed No. 69 dated March 27, 2026, drawn up before Aulia Taufani, S.H., a Notary in South Jakarta, which amendment has been notified to and received by the Minister of Law of the Republic of Indonesia ("**MoL**") through the Letter of Acceptance of Notification of Amendment to the Articles of Association No. AHU-AH.01.03-0093588 dated March 31, 2026 ("**The Company's AoA**").

B. Business Activities

Based on Article 3 of the Company's AoA, the Company's currently carrying out the following business activities:

- a. Private Hospital Activities;
- b. General Practitioner Practice Activities;
- c. Specialist Practice Activities;
- d. Dentist Practice Activities; and
- e. Special Transportation Activities for the Carriage of the Patients (Medical Evacuation).

C. Capital Structure and Shares Ownership

Based on the Company's Shareholders, the structure of the Company's shares ownership as of 31 March 2026 is as below:

Description	Nominal Value per Share		
	Number of Shares	Nominal Value (IDR)	%
Authorized Capital	25,000,000,000	500,000,000,000	-
Issued and Paid-Up Capital			
The Shareholders:			
1. PT Elang Mahkota Teknologi Tbk	14,557,032,045	291,140,640,900	84.81
2. Public	2,607,600,500	52,152,010,000	15.19
Total Issued and Paid Up Capital	17,164,632,545	343,292,650,900	100
Total Portfolio Shares	7,835,367,455	156,707,349,100	-

The Company's Controlling Shareholder, as defined in Article 1 point 4 of POJK No. 9/POJK.04/2018, is PT Elang Mahkota Teknologi Tbk, holding 14,557,032,045 shares, representing 84.81%.

D. Management and Supervision

Deed No. 21 dated June 18, 2025, drawn up before Aulia Taufani, S.H., a Notary in South Jakarta, which has been notified to and received by the Minister of Law through the Letter of Acceptance of Notification of Changes in Company Data No. AHU-AH.01.09-0303802 dated June 26, 2025, the composition of the Board of Directors and Board of Commissioners of the Company is as follows:

Board of Commissioners

President Commissioner and Independent Commissioner	:	Robert Pakpahan
Independent Commissioner	:	Unggung Cahyono
Independent Commissioner	:	Heru Kristiyana
Commissioner	:	Alexander Tedja

Board of Directors

President Director	:	Jusup Halimi
Vice President Director	:	Juniwati Gunawan
Director	:	Meta Dewi Thedja
Director	:	drg. Nailufar, MARS
Director	:	Kusmiati
Director	:	Armen Antonius Djan

As of the date of this Disclosure of Information, the Company, the members of the Board of Directors and the Board of Commissioners of the Company are not involved in any material cases or disputes, either in court or out of court, which may adversely affect the business continuity of the Company and/or Controlled Companies as well as the implementation.

INFORMATION REGARDING MESOP PROGRAM

The MESOP Program is a program for the granting of the Company's new shares free of charge to employees, members of the Board of Directors, and members of the Board of Commissioners of the Company and/or its Controlled Companies who meet the requirements to own shares in the Company, through the issuance of New Shares by the Company in a maximum amount of 34.329.265 (thirty four million three hundred twenty nine thousand two hundred sixty five) shares with a par value of Rp20,- (twenty Rupiah) per share, in which the exercise price will be determined by the Company's Board of Directors with the approval of the Company's Board of Commissioners in accordance with the provisions of Point V.2 Attachment II of the Listing Regulation of PT Bursa Efek Indonesia No. I-A, Decree No. Kep-00045/BEI/03-2026 dated March 31, 2026 concerning Amendments to the Regulation on the Listing of Shares and Equity Securities Other than Shares Issued by Listed Companies ("**Regulation No. I-A**").

A. MESOP Program Participants

Participants in the MESOP Program are all employees, members of the Board of Directors, and members of the Board of Commissioners who meet the following requirements:

1. members of the Board of Commissioners of the Company (except for the Independent Commissioners) and Controlled Companies approved by the Nomination and Remuneration Committee of the Company who served at the date of free shares distribution as part of the compensation;
2. members of the Board of Directors of the Company and Controlled Companies who are proposed by the Board of Directors and approved by the Nomination and Remuneration Committee of the Company who served at the date of free shares distribution as part of the compensation; and
3. permanent employees of the Company and Controlled Companies appointed by the Board of Directors of the Company with the following requirements: (i) have a position with a minimum rank of Grade N-3 and above; (ii) recorded in the employees data of the Company and the Controlled Companies; and (iii) have worked for at least 6 (six) months prior to the date of free shares distribution as part of compensation;

hereinafter referred to as "**MESOP Program Participants**".

B. Shares Distribution Period

By referring to the provisions of POJK No. 14/2019, the MESOP Program will be implemented over a period of 5 (five) years from the date of the GMS approving the MESOP Program. In this regard, if approved at the General Meeting of Shareholders of the Company to be held on 9 June 2026, the implementation period of the MESOP Program shall be from 2026 to 2031.

If deemed relevant to the Company's Board of Directors, in which there must be a prior approval from the Company's Nomination and Remuneration Committee, the New Shares will be issued annually at 25% (twenty five percent) for 4 (four) consecutive years. Each New Share issued is distributed to the MESOP Program Participants with a vesting period which will be determined later by the Company. Additionally, the dividends that will be distributed by the Company to MESOP Program Participants are only dividends from shares that have been issued, in which it will be distributed officially to the MESOP Program Participants.

The New Shares will be distributed to MESOP Program Participants in several stages to be determined by the Company's Board of Directors with prior approval from the Company's Nomination and Remuneration Committee. The Company's Nomination and Remuneration Committee will calculate the shares to be allocated to eligible MESOP Program Participants based on the participants' work performance and by taking into account their duties and responsibilities in making decisions that have a significant impact on the Company's performance.

C. Determination of Exercise Price of The New Shares

The determination of the exercise price of shares under the MESOP Program will be carried out by the Board of Directors with the prior approval of the Company's Board of Commissioners, in reference to the provisions of Point V.2 of Attachment II of Rule No. I-A, which stipulate that the

exercise price shall be at least 90% (ninety percent) of the average closing price of the Company's shares over a period of 25 (twenty five) consecutive trading days in the regular market prior to the date of the report to the Indonesia Stock Exchange ("IDX") regarding the planned implementation of the MESOP, or shall be determined in accordance with the prevailing laws and regulations in the fields of limited liability companies and capital markets, as well as applicable accounting standards.

D. Status of The MESOP Program Shares

The New Shares in the MESOP Program have the same rights, position, and degrees in all respects as other shares that have been issued and fully paid into the Company, including in terms of acquiring rights to dividends and issuing voting rights at the GMS and other corporate actions to be implemented by the Company.

E. Period of The New Shares Issuance and The MESOP Program Implementation

The period for the issuance of New Shares, the number of MESOP Program Participants, and other matters related to the implementation of the MESOP Program will be determined further by the Company with due observance of the prevailing laws and regulations in the capital market sector.

F. Requirements of The MESOP Program

By taking into account the applicable laws and regulations, this MESOP Program can be carried out by first fulfilling the following requirements:

1. The Company has obtained an approval from the General Meeting of Shareholders to implement the MESOP Program;
2. The Company has obtained IDX approval for the pre-listing application of the additional shares originating from the MESOP Program;
3. If any of the MESOP Program Participants resigns from his/her position at the Company or Controlled Companies, all shares to be granted but have not met the vesting period will be forfeited and the said MESOP Program Participant is not entitled to such shares. If any of the MESOP Program Participants is dismissed from his/her position at the Company or Controlled Companies, all shares to be granted but have not met the vesting period will be forfeited and the said MESOP Program Participant is not entitled to such shares. As for each forfeited share, there will be no transfer of rights to the other MESOP Program Participants; and
4. Other requirements which will be further determined by the Board of Directors after receiving a recommendation from the Company's Nomination and Remuneration Committee.

G. Management Analysis and Discussion Regarding the Company's Financial Condition

The MESOP Program is implemented by the Company by giving free shares without option rights to program participants, so that all costs incurred, including the cost of acquiring shares, are fully borne by the Company.

The source of funding to be utilized by the Company for the implementation of the MESOP Program shall be derived from the Company's internal cash and/or other sources of funding to be determined by the Company.

In implementing the MESOP Program, the Company undertakes to comply with the prevailing laws and regulations, including fulfilling and/or complying with any and all tax obligations arising from the implementation of the MESOP Program.

The implementation of the capital increase through the MESOP Program is expected to have a positive impact on the Company's capital structure, as the increase in the number of issued shares will directly enhance the Company's equity.

Accordingly, with the increase in equity, the Company's capital structure will become stronger, which in turn will support the Company's long term growth strategy and enhance the Company's value. Furthermore, the Company expects that the MESOP Program will promote the loyalty and motivation of management and employees, without adversely affecting the Company's financial stability.

Pro Forma Capital and Shareholder Structure in Relation to the MESOP Program

With reference to the Company's Shareholders Register as of 31 March 2026, from PT Bima Registra, the following is the pro forma of the Company's capital and shareholder composition before and after the issuance of New Shares:

REMARKS	Before the Issuance of the MESOP Program Shares			After the Issuance of the MESOP Program Shares		
	Nominal IDR20, -/share (IDR)			Nominal IDR20, -/share (IDR)		
	Number of Shares	Nominal Value (IDR)	%	Number of Shares	Nominal Value (IDR)	%
Authorized Capital	25,000,000,000	500,000,000,000	-	25,000,000,000	500,000,000,000	-
Issued and Paid-Up Capital						
The Shareholders:						
1 PT Elang Mahkota Teknologi Tbk	14,557,032,045	291,140,640,900	84.81	14,557,032,045	291,140,640,900	84.64
2 Public	2,607,600,500	52,152,010,000	15.19	2,607,600,500	52,152,010,000	15.16
3 MESOP Program	-	-	-	34,329,265	686,585,300	0.20
Total Issued and Paid-Up Capital	17,164,632,545	343,292,650,900	100	17,198,961,810	343,979,236,200	100
Total Portfolio Shares	7,835,367,455	156,707,349,100	-	7,801,038,190	156,020,763,800	-

With respect to the overall implementation of the MESOP Program, in the event that all shares are issued as New Shares from the Company's treasury shares, the Company's shareholders will experience a proportional dilution of their share ownership in accordance with the number of new shares issued, amounting to a maximum of 0.2% (zero point two percent).

H. No Objections from Certain Parties and Prior Approval and/or Permits

Until the publication of this information disclosure, the Company has not received any objections from certain parties regarding the PMTHMETD by the Company.

Furthermore, there are no restrictions that could hinder the PMTHMETD plan that will be carried out by the Company and the obligation to obtain prior approval and/or permits from other parties, creditors and/or other authorized agencies, other than the Approval of Independent Shareholders through the GMS as required by POJK No. 14/2019.

THE STATEMENT OF BOARD OF DIRECTORS AND BOARD OF COMMISSIONERS

The information described in this Disclosure of Information has been approved by the Board of Commissioners and Directors of the Company, who are responsible for the validity of all information disclosed. The Board of Commissioners and Directors of the Company hereby declare that all material information and opinions expressed in this Disclosure of Information are true and can be accounted for and there is no other information that has not been disclosed which may lead to incorrect or misleading information. The Board of Commissioners and Directors of the Company have reviewed the MESOP Program, including assessing the risks and benefits for the Company and all shareholders. Therefore, based on trust and confidence that the MESOP Program is the best choice to achieve benefits for the Company, Directors and Board of Commissioners of the Company recommend to shareholders to approve the MESOP Program as described in this Disclosure of Information.

EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS

In accordance with the provisions of the applicable laws and regulations, the approval of this MESOP Program will be requested at the Company's EGMS which will be held on:

Day, Date : Tuesday, 9 June 2026
 Time : 14.00 Western Indonesian Time – until end
 Venue : Studio SCTV, SCTV Tower Floor 8, Senayan City,
 Jl. Asia Afrika Lot. 19, Central Jakarta, 10270, Indonesia.

Meeting Agenda :

1. Approval of the establishment of the Management and Employee Stock Ownership Program (“**MESOP Program**”) in a maximum amount of 34,329,265 shares or 0.2% of the Company's fully issued and paid-up capital.
2. Approval of the Company's plan to conduct a Capital Increase Without Pre-emptive Rights in a maximum amount of 1,682,133,989 shares or 9.8% of the Company's issued and paid-up capital (“**PMTHMETD**”), and approval of the amendment to Article 4 of the Company's Articles of Association in connection with the implementation of the PMTHMETD.
3. Approval to pledge most or all of the Company's and/or the Company's subsidiaries' assets and/or properties, including but not limited to the provision of corporate guarantees to be granted by the Company and/or its subsidiaries to banking institutions and/or other financial institutions in connection with financing plans from such banking institutions and/or other financial institutions, as required under Article 102 of the Company Law.

The announcement and notice of the EGMS were published on (i) the eASY.KSEI website, (ii) the IDX website, and (iii) the Company's website on 26 April 2026 and 11 May 2026.

This Information Disclosure has been announced through (i) the eASY.KSEI website, (ii) the IDX website, and (iii) the Company's website on 26 April 2026.

In accordance with the agenda of the EGMS, the quorum requirements are as follows:

Quorum for the First and Second Agenda

Referring to Article 8A paragraphs (2) and (3) of POJK No. 14/2019, the quorum requirements for attendance and approval of the MESOP Program and PMTHMETD are as follows:

1. The GMS may be convened if attended by more than 1/2 (half) of the total shares with valid voting rights held by independent shareholders and shareholders who are not affiliated with the public company, members of the Board of Directors, members of the Board of Commissioners, major shareholders, or controlling shareholders.
2. Resolutions of the GMS as referred to in point 1 shall be valid if approved by more than 1/2 (half) of the total shares with valid voting rights held by independent shareholders and non-affiliated shareholders.
3. If the quorum for the first GMS is not met, a second GMS may be convened if attended by more than 1/2 (half) of the total shares with valid voting rights held by independent shareholders and shareholders who are not affiliated with the public company, members of the Board of Directors, members of the Board of Commissioners, major shareholders, or controlling shareholders.
4. Resolutions of the second GMS shall be valid if approved by more than 1/2 (half) of the total shares with valid voting rights held by independent shareholders and shareholders who are not affiliated with the public company, members of the Board of Directors, members of the Board of Commissioners, major shareholders, or controlling shareholders.
5. In the event that the attendance quorum for the second GMS is not achieved, a third GMS may be convened, provided that such third GMS shall be valid and authorized to adopt resolutions if attended by independent shareholders and shareholders who are not affiliated with the public company, members of the Board of Directors, members of the Board of Commissioners, major shareholders, or controlling shareholders, representing shares with valid voting rights, within

the attendance quorum determined by the Financial Services Authority (OJK) upon the request of the public company.

6. Resolutions of the third GMS shall be valid if approved by independent shareholders and shareholders who are not affiliated with the public company, members of the Board of Directors, members of the Board of Commissioners, major shareholders, or controlling shareholders which representing more than 50% (fifty percent) of the shares held by such shareholders present at the GMS.
7. The convening of the GMS must comply with POJK No. 15/2020, POJK No. 14/2025, and the Company's Articles of Association, unless otherwise stipulated by OJK regulations.

Quorum for the Third Agenda

1. The GMS may be convened if attended by shareholders representing at least 3/4 (three fourths) of the total shares with valid voting rights. Resolutions are valid if approved by more than 3/4 (three fourths) of the shares present.
2. If the quorum is not met, a second GMS may be held if attended by shareholders representing at least 2/3 (two thirds) of the total shares with valid voting rights. Resolutions are valid if approved by more than 3/4 (three fourths) of the shares present at the second GMS.
3. If the quorum for the second GMS is not met, a third GMS may be held, which shall be valid and authorized to adopt resolutions if attended by shareholders representing shares with valid voting rights and in accordance with the quorum requirements determined by the Financial Services Authority (OJK) upon the Company's request.

This Information Disclosure is prepared in English and Bahasa Indonesia. In the event there is a different interpretation between the English and Bahasa Indonesia version, the relevant information in Bahasa Indonesia shall prevail and the relevant information in English shall be amended and interpreted in accordance with the Bahasa Indonesia version.

Jakarta, 26 April 2026
PT Sarana Meditama Metropolitan Tbk
The Board of Directors